The 66th ORCA Congress will be held in Cartagena, Colombia, from July 3 to 6, 2019. Further information about the congress and venue will be available at www.orca2019.org. Registration will be made through this website.

Abstracts must be submitted via the ORCA website (http://www.orca-caries-research.org/; see below for guidance). Abstracts cannot be submitted directly to the Editor.

If participants require a letter of invitation (e.g., to obtain visa or to satisfy their institution’s requirements), the ORCA Board will provide one on request. Please contact the Secretary-General, Ass. Prof. Dr. Monique van der Veen (e-mail secretary@orca-caries-research.org) in good time. The provision of such a letter does not imply that travel expenses will be covered by ORCA.

The abstracts for presentation at the 66th ORCA Congress will be presented prior to the meeting (online only) on the Caries Research homepage (www.karger.com/cre).

Abstracts should be submitted using the ORCA website (http://www.orca-caries-research.org) before January 10, 2019. All abstracts will be reviewed by the Scientific Programme Committee. Authors will be notified of acceptance or rejection of their abstract early in February 2019 and at that time may be asked to revise their abstract. Any such revisions must be submitted no later than Monday, March 4, 2019.

Presenters should note the following:

1. The Congress focuses on research into dental caries and related topics

2. Abstracts must describe research that has not been published or presented already and has not been submitted to another meeting at the time of submission for the ORCA Congress

3. Authors may present only 1 paper at the Congress but may co-author other papers

4. The presentation at the Congress should conform to the material in the published abstract. If a mistake is discovered after submission, please contact the Editor to discuss prepublication revision. Major revision of abstracts is possible up to the end of February and minor revisions (e.g., correction of numerical values) up to the end of March. If revision is not possible, the poster should fully explain the reason for any deviations from the abstract, either in the results or in the conclusions

5. Presenters who are not ORCA members should submit their abstract in the usual manner and send a supporting statement signed by a senior member of ORCA (“sponsor”) to Prof. David Beighton (e-mail david.beighton@kcl.ac.uk)

6. Those who submit an abstract are committed to present the paper in person at the Congress. In the case of a non-member of ORCA, it is the sponsor’s responsibility that this requirement is met. Presenters should:

–ensure that they will have the necessary funds to attend the Congress;

–apply for any necessary visas in good time, to ensure that they can travel to the Congress to present their paper;

–ensure that any abstract describing commercially funded research has been approved by the funding company before submitting it

7. Abstracts must be written exactly according to the instructions given below

8. All presentations will be in poster form

9. Abstracts cannot be withdrawn after March 18, 2019. If an abstract is not withdrawn by that date, and the paper is not presented, neither the named presenter nor their sponsor will be allowed to present any paper at the following ORCA Congress

Abstracts must be submitted via the ORCA website, not via e-mail. Log on to www.orca-caries-research.org and follow the links. The abstract and supplementary material (see below) should be submitted by the end of January 10, 2019.

Presenters will be asked for the following items:

1. Surnames and initials of the presenting author, corresponding author, and other authors

2. The e-mail address of the corresponding author

3. Brief affiliations of authors (institute, city, country only)

4. Title of abstract; this should be 15 words or less

5. Text of abstract; this should state the aim of the work, the experimental approach, the main results, and the conclusions. The results should include key numerical and statistical data, but do not attempt to report data exhaustively. The conclusions should be explicit. Vague expressions such as “the results will be discussed” could result in rejection of the abstract. The text should not exceed 280 words. Include references only when they are absolutely essential and follow an abbreviated Caries Research format, but omitting the authors’ initials and the title, and using “et al.” for multiple-author works. Example: Main et al.: J Oral Rehab 1983; 10: 307–313. Tables, photographs, graphs, or diagrams are not allowed.

6. Acknowledgement of sources of funding

7. A 25-word summary of the abstract. This should not reiterate the aim of the study but should summarize the conclusion

8. One or 2 of the following key phrases, which are required to assist programming: clinical studies; de- and re-mineralization; dental plaque; diagnostics; diet; epidemiology; erosion; fluoride; hard tissues; microbiology; pulp-dentinal reactions; caries risk assessment; saliva and pellicle.

The ORCA Nathan Cochrane Junior Scientist’s Award, inaugurated in 2007 as the Young Investigator’s Award, is intended to encourage young researchers. The prize winner receives a certificate and is entitled to receive reimbursement of the congress fees of a future ORCA Congress. Applicants for the ORCA Nathan Cochrane Junior Scientist’s Award must present a poster at an ORCA Congress and have to fulfil the following criteria:

1. have not more than 5 international publications identified in Medline on the day of the deadline for abstract submission for the next ORCA Congress;

2. be aged 35 or under on the last day of the ORCA Congress;

3. be present on the closing ceremony of the ORCA Congress;

4. not be a previous winner of the ORCA Young Investigator’s Award or Junior Scientist’s Award;

5. must be the first author of the presentation;

6. presentation must not be a review. Presenters enter the competition by ticking the appropriate box when submitting their abstract via the online submission system.

The Swedish Patent Revenue Fund for Research in Preventive Odontology was established in 1963. Among several activities to support research in this field, the Fund every third year awards a major international prize named in honour of its founder and major donator, professor Yngve Ericsson, one of the founders of ORCA.

The recipient should be an eminent researcher in the field of preventive odontology. The Prize was instituted in 1986 in collaboration with the Swedish Medical Research Council. Beginning in 2010, the Prize has been awarded in collaboration with ORCA – the European Organization for Caries Research. The Patent Revenue Fund and ORCA herby solicit nominations for the 2019 Yngve Ericsson Prize.

The following researchers have in the past received the Yngve Ericsson Prize: Harold Hodge & Finn Brudevold (1988); Gunnar Rølla & Arje Scheinin (1991); Bo Krasse & Jan Lindhe (1994); William Bowen & Thomas Marthaler (1997); Bob ten Cate & Sigmund Socransky (2000); John Featherstone & Ole Fejerskov (2003); Adrian Lussi & Jorma Tenovuo (2006); Jaime A. Cury & Hannu Hausen (2010); Vibeke Bælum & Bente Nyvad (2013); and Jo Frencken & Panos Papapanou (2016).

The award for the year 2019 will be SEK 300,000 (approx. EUR 32,000) for one person and, if shared by two recipients, SEK 200,000 per person. The Prize winner(s) will be selected by a Prize Committee of distinguished scientists, three members of which are appointed by the Patent Revenue Fund and two members appointed by ORCA.

The Prize is awarded to persons who have performed outstanding laboratory or clinical research that has contributed specifically to the prevention of dental and oral disease. Candidates are judged on the originality, quality and range of their scientific contributions as well as the range and clinical importance of the results. Individuals who are still active in research are preferred candidates.

No preference will be given to candidates from any country. A nomination should contain the name of the candidate and must be accompanied by a statement giving reasons why the candidate would be a worthy awardee, including a list of the candidate’s relevant scientific publications and a short CV.

Nominations of candidates must be received no later than February 1st, 2019 by the Secretary of the Patent Revenue Fund, Prof. Peter Lingström, Institute of Odontology, Box 450, SE-405 30 Göteborg, Sweden. E-mail: peter.lingstrom@odontologi.gu.se.

This Committee, which is chaired by the Vice-President, aims to stimulate and facilitate research related to the aims of ORCA:

1. through periodic summer schools held in association with the ORCA Congresses;

2. by helping organize summer schools or symposia in countries where cariology is developing or where ORCA is not yet present;

3. by funding and advising young researchers from countries where cariology is developing or where ORCA is not yet present.

Announcements relating to these activities will be made each year in issue 5 of Caries Research as well as by other methods. Proposals for summer schools should be addressed to the Vice-President: Prof. Dr. Christian H. Splieth, University of Greifswald, Rotgerberstrasse 8, DE–17487 Greifswald, Germany (e-mail splieth@uni-greifswald.de).

These fellowships will be available in 2019, to assist attendance at an ORCA Congress.

Researchers in the field of caries or related subjects will be eligible, and preference will be given to workers from underprivileged countries. Each fellowship will have a value up to EUR 1,200 as a contribution to costs of attending the Congress. The applicant should prepare either:

1. an abstract of research results, prepared according to the “Instructions for Authors of Abstracts” (see previous page) or

2. a proposal for a research project to be carried out by the applicant. The proposal should have a clear aim and describe the methods to be used. The project should be original work, to be executed in their own institute by the applicant and young coworkers. The research should potentially lead to a publication in an indexed journal.

Finally applicants should have an adequate mastery of English because, if successful, they will discuss their proposal with experts at the Congress. The application should include: (1) the abstract of research results or the research proposal, whichever is applicable; (2) a curriculum vitae; (3) a letter of recommendation from a senior staff member at the home institution; (4) a description of the applicant’s present position and current research work.

It is strongly recommended that those who wish to apply ask for advice as early as possible from the ORCA Committee for Stimulation and Promotion of Research into Caries: Prof. Dr. Christian H. Splieth, University of Greifswald, Rotgerberstrasse 8, DE–17487 Greifswald, Germany (e-mail splieth@uni-greifswald.de).

Applicants should submit their application by January 10, 2019, to the Secretary-General: Ass. Prof. Dr. Monique van der Veen, ACTA, Department of Preventive Dentistry, Gustav Mahlerlaan 3004, 1081LA Amsterdam, The Netherlands (e-mail secretary@orca-caries-research.org). Applicants who wish to present an abstract should also submit it via the website.

Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.